EUCTR2007-001412-23-GB进行中（未招募）不适用
ong Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis – A Safety and Efficacy Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 340
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects may be included in the study if all of the following criteria are met. The subject must:
- •1. Have given written informed consent to participate in this study in accordance with local regulations
- •2. Have a confirmed diagnosis of cystic fibrosis
- •3. Be aged >= 6 years
- •4. Have FEV1 >=30 % and <90% predicted
- •5. Be able to perform all the techniques necessary to measure lung function
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects are excluded from participating in this study if one or more of the following criteria are met. The subject must NOT:
- •1. Be investigators, site personnel directly affiliated with this study, and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biologically or legally adopted.
- •2. Be considered terminally ill” or listed for lung transplantation
- •3. Have had a lung transplant
- •4. Be using nebulised hypertonic saline concurrently or in the 2 weeks prior to visit 1
- •5. Have had a significant episode of haemoptysis (>60 mL) in the three months prior to enrolment
- •6. Have had a myocardial infarction in the three months prior to enrolment
- •7. Have had a cerebral vascular accident in the three months prior to enrolment
- •8. Have had major ocular surgery in the three months prior to enrolment
- •9. Have had major abdominal, chest or brain surgery in the three months prior to enrolment
- •10. Have a known cerebral, aortic or abdominal aneurysm
- •11. Be breast feeding or pregnant, or plan to become pregnant while in the study
- •12. Be using an unreliable form of contraception (female subjects at risk of pregnancy only)
- •13. Be participating in another investigative drug study, parallel to, or within 4 weeks of study entry
- •14. Have a known allergy to mannitol
- •15. Be using beta blockers
- •16. Have uncontrolled hypertension – systolic BP > 190 and or diastolic BP > 100
- •17. Have a condition or be in a situation which in the Investigator’s opinion may put the subject at significant risk, may confound results or may interfere significantly with the patient’s participation in the study
- •18. Be ‘Aridol-MTT test positive’.
研究者
相似试验
进行中（未招募）
不适用
ong Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis – A Safety and Efficacy StudyMedDRA version: 9.1Level: LLTClassification code 10011762Term: Cystic fibrosisCystic FibrosisEUCTR2007-001412-23-IEPharmaxis Pharmaceuticals Limited250
进行中（未招募）
1 期
ong Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis – A Safety and Efficacy StudyMedDRA version: 14.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2006-004078-28-GBPharmaxis UK Limited250
进行中（未招募）
1 期
ong Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis – A Safety and Efficacy StudyMedDRA version: 9.1Level: LLTClassification code 10011762Term: Cystic fibrosisCystic FibrosisEUCTR2007-001412-23-DEPharmaxis Pharmaceuticals Limited340
已完成
3 期
Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy StudyCystic FibrosisNCT00446680Syntara340
已完成
不适用
Inhaled mannitol improves sputum clearance in intubated patientsACTRN12609000145202A/Prof Paul Phipps25